1. Home
  2. SCYX vs HTCO Comparison

SCYX vs HTCO Comparison

Compare SCYX & HTCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • HTCO
  • Stock Information
  • Founded
  • SCYX 1999
  • HTCO 2022
  • Country
  • SCYX United States
  • HTCO Singapore
  • Employees
  • SCYX N/A
  • HTCO N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • HTCO
  • Sector
  • SCYX Health Care
  • HTCO
  • Exchange
  • SCYX Nasdaq
  • HTCO NYSE
  • Market Cap
  • SCYX 36.8M
  • HTCO 38.7M
  • IPO Year
  • SCYX 2014
  • HTCO N/A
  • Fundamental
  • Price
  • SCYX $0.88
  • HTCO $0.27
  • Analyst Decision
  • SCYX
  • HTCO
  • Analyst Count
  • SCYX 0
  • HTCO 0
  • Target Price
  • SCYX N/A
  • HTCO N/A
  • AVG Volume (30 Days)
  • SCYX 204.8K
  • HTCO 2.1M
  • Earning Date
  • SCYX 05-15-2025
  • HTCO 01-01-0001
  • Dividend Yield
  • SCYX N/A
  • HTCO N/A
  • EPS Growth
  • SCYX N/A
  • HTCO N/A
  • EPS
  • SCYX N/A
  • HTCO N/A
  • Revenue
  • SCYX $2,630,000.00
  • HTCO $108,176,683.00
  • Revenue This Year
  • SCYX $460.12
  • HTCO N/A
  • Revenue Next Year
  • SCYX $253.87
  • HTCO N/A
  • P/E Ratio
  • SCYX N/A
  • HTCO N/A
  • Revenue Growth
  • SCYX N/A
  • HTCO 13.56
  • 52 Week Low
  • SCYX $0.72
  • HTCO $0.21
  • 52 Week High
  • SCYX $2.60
  • HTCO $4.50
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 48.64
  • HTCO N/A
  • Support Level
  • SCYX $0.72
  • HTCO N/A
  • Resistance Level
  • SCYX $1.02
  • HTCO N/A
  • Average True Range (ATR)
  • SCYX 0.08
  • HTCO 0.00
  • MACD
  • SCYX 0.00
  • HTCO 0.00
  • Stochastic Oscillator
  • SCYX 51.70
  • HTCO 0.00

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About HTCO CARAVELLE INTERNATIONAL GROUP

High-Trend International Group formerly Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company derives freight revenue from voyage contracts and provides vessel service. Majority of revenue is from providing shipping services for customers in Asia, principally in Singapore, Dubai, Korea, Japan, and India.

Share on Social Networks: